GNMLF (Genomma Lab InternacionalB de CV) Total Liabilities: $725.6 Mil (As of Mar. 2026)


GNMLF Genomma Lab Internacional SAB de CV GNMLF
59 GF Score
Price $0.84
GF Value $0.90
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Genomma Lab InternacionalB de CV Total Liabilities?

Genomma Lab InternacionalB de CV GNMLF 59 Total Liabilities is $725.6 Mil as of Mar. 2026. GuruFocus rates GNMLF with a GF Score™ of 59/100 and a GF Value™ of $0.90 (Fairly Valued). The stock has 4 warning signs investors should review.

Genomma Lab InternacionalB de CV's Total Liabilities for the quarter that ended in Mar. 2026 was $725.6 Mil.

Genomma Lab InternacionalB de CV's quarterly Total Liabilities increased from Sep. 2025 ($687.02 Mil) to Dec. 2025 ($698.25 Mil) and increased from Dec. 2025 ($698.25 Mil) to Mar. 2026 ($725.64 Mil).

Genomma Lab InternacionalB de CV's annual Total Liabilities declined from Dec. 2023 ($666.54 Mil) to Dec. 2024 ($581.76 Mil) but then increased from Dec. 2024 ($581.76 Mil) to Dec. 2025 ($698.25 Mil).

Genomma Lab InternacionalB de CV Total Liabilities Historical Data

* Premium members only.

The historical data trend for Genomma Lab InternacionalB de CV's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Genomma Lab InternacionalB de CV Total Liabilities Chart

Genomma Lab InternacionalB de CV Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 559.17 587.51 666.54 581.76 698.25

Genomma Lab InternacionalB de CV Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 634.05 690.90 687.02 698.25 725.64
GNMLF
59GF Score
Genomma Lab Internacional SAB de CV GNMLF
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Genomma Lab InternacionalB de CV Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Genomma Lab InternacionalB de CV's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=396.845+(266.351+29.379
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+3.622+2.052)
=698.2

Total Liabilities=Total Assets (A: Dec. 2025 )-Total Equity (A: Dec. 2025 )
=1315.723-617.473
=698.3

Genomma Lab InternacionalB de CV's Total Liabilities for the quarter that ended in Mar. 2026 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=424.346+(262.228+39.07
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+2.052)
=725.6

Total Liabilities=Total Assets (Q: Mar. 2026 )-Total Equity (Q: Mar. 2026 )
=1375.307-649.663
=725.6

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of $725.6 Mil mean?
Genomma Lab InternacionalB de CV (GNMLF) has a Total Liabilities of $725.6 Mil as of Mar. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Genomma Lab InternacionalB de CV and its competitors.
Is Genomma Lab InternacionalB de CV's Total Liabilities too high?
Genomma Lab InternacionalB de CV's current Total Liabilities is $725.6 Mil. Overall, Genomma Lab InternacionalB de CV has a GF Score™ of 59/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Genomma Lab InternacionalB de CV's Total Liabilities compare to ZTS and UTHR?
Genomma Lab InternacionalB de CV's Total Liabilities of $725.6 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Drug Manufacturers company?
A good Total Liabilities depends on the Drug Manufacturers industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Genomma Lab InternacionalB de CV and its competitors. Genomma Lab InternacionalB de CV's current Total Liabilities is $725.6 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genomma Lab InternacionalB de CV stock overvalued right now?
Based on GuruFocus' analysis, Genomma Lab InternacionalB de CV (GNMLF) is currently considered Fairly Valued. The stock's GF Value™ is $0.90, compared to a current price of $0.84 — trading 7% below its estimated fair value. The current Total Liabilities is $725.6 Mil. Genomma Lab InternacionalB de CV's overall GF Score™ is 59/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Genomma Lab InternacionalB de CV (GNMLF), the current Total Liabilities is $725.6 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Genomma Lab InternacionalB de CV (GNMLF) Overvalued in 2026?

Based on GuruFocus' analysis, Genomma Lab InternacionalB de CV stock appears to be undervalued. The current stock price of $0.84 is trading 7% below its estimated GF Value™ of $0.90. GuruFocus considers Genomma Lab InternacionalB de CV to be Fairly Valued.

Key valuation signals for GNMLF:

  • Total Liabilities: $725.6 Mil
  • GF Value™: $0.90 vs. price of $0.84 (7% below fair value)
  • GF Score™: 59/100 with 4 warning signs

No single metric tells the full story. See the GNMLF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Genomma Lab InternacionalB de CV Business Description

Other Exchanges LABB:MexicoGEKA:Germany
Address Avenida Antonio Dovali Jaime, Number 70, Tower C, Floor 2, Office A. Colonia Santa Fe, Del. Alvaro Obregon, Mexico, MEX, MEX, CP 01210
Genomma Lab Internacional SAB de CV is a specialty and generic drug manufacturer. The company's stated goal is to improve and preserve the health and well-being of people through innovative, safe, and effective products. Genomma operates a wide variety of brands to serve different consumer needs, including pregnancy, pain medication, and deodorant. The company considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.
59GF Score

Get the complete analysis for GNMLF

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.84
Price
$0.90
GF Value